Author:
Penazzato Martina,Townsend Claire L,Sam-Agudu Nadia A,Ruel Theodore D,Archary Moherndran,Bekker Adrie,Cressey Tim R,Colbers Angela,Sugandhi Nandita,Rojo Pablo,Rakhmanina Natella,Watkins Melynda,Frigati Lisa,Mukui Irene,Hafiz Asma,Vicari Marissa,Capparelli Edmund V,Abrams Elaine J,Abrams Elaine,Archary Moherndran,Bekker Adrie,Capparelli Edmund,Colbers Angela,Cressey Tim,Frigati Lisa,Hafiz Asma,Mukui Irene,Penazzato Martina,Rakhmanina Natella,Rojo Pablo,Ruel Theodore,Sam-Agudu Nadia,Sugandhi Nandita,Townsend Claire,Vicari Marissa,Watkins Melynda
Subject
Virology,Infectious Diseases,Immunology,Epidemiology
Reference28 articles.
1. Optimizing research to speed up availability of pediatric antiretroviral drugs and formulations;Penazzato;Clin Infect Dis,2017
2. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach,2021
3. Bacha J, Mayalla B, Jiwa N, Mwita L, Campbell LR. The ‘DTGs’ of DTG for children and adolescents living with HIV (CALHIV): descriptions, trends, and gaps of rolling out dolutegravir in CALHIV in Mbeya, Tanzania. 23rd International AIDS conference; July 20, 2020 (abstr PEB0297).
4. Iyer S, Pry J, Nyirenda G, et al. Dolutegravir and viral load suppression among pediatric patients in care in Zambia. Conference on Retroviruses and Opportunistic Infections (CROI); March 6–10, 2021 (abstr 600).
5. Dolutegravir as first- or second-line treatment for HIV-1 infection in children;Turkova;N Engl J Med,2021